MA
Microba Life Sciences Limited
MAP.AX · ASX
$0.06 +0.00% (+$0.00)
1M +12.24%
Market Cap $39.4M
P/E Ratio -
Div. Yield -
ROE 67.53%
Piotroski F-Score Weak
2/9Valuation
81 /100
Cheap P/B 1.62x
P/S 2.67x
P/FFO N/A
Growth
78 /100
Growing Book val. growth 14.18%
Rev. growth 39.64%
FCF growth N/A
Profitability
0 /100
Weak Net margin 140.40%
Op. margin 137.58%
FCF margin 85.45%
Quality
5 /100
Poor ROE 67.53%
ROA 52.05%
Asset turnover 0.37x
Debt
58 /100
Moderate Current ratio 1.24x
Int. coverage -85.11x
Debt/Equity 0.17x
Stability
21 /100
Unstable Rev. volatility 66.58%
EPS volatility 29.69%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o MAP.AX
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Luke Reid
Employees
80
Headquarters
Brisbane
Prihajajoči dogodki
03 MAR.
Earnings
Upcoming earnings report